R.F. Lafferty Devalues Auxilium, QLT Deal
R.F. Lafferty graded Auxilium Pharmaceuticals' (NASDAQ: AUXL) acquisition of QLT (NASDAQ: QLT) to be neutral, based on lack of sufficient cash for Auxilium to complete the deal.
Auxilium announced on Thursday that it will acquire QLT for 3.1359 shares of Auxilium stock, equivalent to a 25 percent premium based on QLT's stock price on June 25, 2014. The merger is expected to close later in the fourth quarter of 2014.
Despite the deal announced to be a stock-for-stock deal, Auxilium lacking the cash power could mean that acquiring QLT creates an opportunity cost, making the deal less valuable.
Shares of Auxilium dropped 3.93 percent to $20.43 in the middle of Thursday's market hours. Shares have rebounded in Friday's action, up less than one percent to $20.76.
Latest Ratings for AUXL
Date | Firm | Action | From | To |
---|---|---|---|---|
Oct 2014 | Mizuho | Downgrades | Buy | Neutral |
Oct 2014 | MKM Partners | Downgrades | Buy | Neutral |
Sep 2014 | RBC Capital | Downgrades | Outperform | Sector Perform |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: R.F. LaffertyAnalyst Color Analyst Ratings